Recent advances in liposomal drug-delivery systems.
Liposomal drug-delivery systems have come of age in recent years, with several liposomal drugs currently in advanced clinical trials or already on the market. It is clear from numerous pre-clinical and clinical studies that drugs, such as antitumor drugs, packaged in liposomes exhibit reduced toxicities, while retaining, or gaining enhanced, efficacy. This results, in part, from altered pharmacokinetics, which lead to drug accumulation at disease sites, such as tumors, and reduced distribution to sensitive tissues. Fusogenic liposomal systems that are under development have the potential to deliver drugs intracellularly, and this is expected to markedly enhance therapeutic activity. Advances in liposome design are leading to new applications for the delivery of new biotechnology products, such as recombinant proteins, antisense oligonucleotides and cloned genes.
Chonn
A
A
INEX Pharmaceuticals Corporation, Vancouver, Canada.
Cullis
P R
PR
D001709:Biotechnology / Q000639:trends; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000639:trends*; D015195:Drug Design; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D008081:Liposomes; D009696:Nucleic Acids / Q000008:administration & dosage; D011506:Proteins / Q000008:administration & dosage
D004337:Drug Carriers; D008081:Liposomes; D009696:Nucleic Acids; D011506:Proteins